|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome显示文摘 | TIEPPO J VERCELINO R DIAS A S | 2007 | Food and Chemical Toxicology2007，45，： | 1 |
| 2 | Long-Term Follow-up of Barrett’s Epithelium: Medical Versus Antireflux Surgical Therapy显示文摘 | Giovanni Zaninotto Paola Parente Renato Salvador Fabio Farinati Chiara Tieppo Nicola Passuello Lisa Zanatta Matteo Fassan Francesco Cavallin Mario Costantini Claudia Mescoli Giorgio Battaglia Alberto Ruol Ermanno Ancona Massimo Rugge | 2012 | Journal of Gastrointestinal Surgery2012，，： | 1 |
| 3 | N-acetylcysteine effects on genotoxic and oxidative stress parameters in cirrhotic rats with hepatopulmonary syndrome 显示文摘 | Vercelino R Tieppo J Dias AS | 2008 | Basic Clin Pharmacol Toxicol2008，102，4： | 1 |
| 4 | Experimental models for assessment of pulmonary alterations in hepatopulmonary syndrome显示文摘 | Vercelino R Tieppo J Forgiarini Junior LA | 2008 | J Bras Pneumol2008，34，7： | 1 |
| 5 | Suppression of Am-phiregulin/Epidermal Growth Factor Receptor Signals Contributes to the Protective Effects of Quercetin in Cirrhotic Rats显示文摘 | Cuevas MJ Tieppo J Marroni NP | 2011 | J Nutr2011，，： | 1 |
| 6 | Evaluation of the pro- tective effects of quercetin in the hepatopulmonary syndrome 显示文摘 | TIEPPO J VERCELINO R DIAS A S | 2007 | Food Chem Toxico12007，45，7： | 1 |
| 7 | Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome显示文摘 | J. Tieppo R. Vercelino A.S. Dias M.F. Silva Vaz T.R. Silveira C.A. Marroni N.P. Marroni J.A.P. Henriques J.N. Picada | 2007 | Food and Chemical Toxicology2007，，7： | 1 |
| 8 | Effect of Boswellia serrata on Antioxidant Status in an Experimental Model of Colitis Rats Induced by Acetic Acid显示文摘 | Renata Hartmann Maria Morgan Martins Juliana Tieppo Henrique Fillmann Norma Marroni | 2012 | Digestive Diseases and Sciences2012，，8： | 1 |
| 9 | Evaluation of the protective effects of quercetin in the hepatopulmonary syndrome显示文摘 | Tieppo J Vercelino R Dlas A S | 2007 | Food Che Tox2007，45，： | 1 |
| 10 | Quercetin Administration Ameliorates Pulmonary Complications of Cirrhosis in Rats1-3显示文摘 | Tieppo Juliana Cuevas María J Vercelino Rafael Tu?ón María J Marroni Norma P González-Gallego Javier | 2009 | The Journal of Nutrition2009，，7： | 1 |
| 11 | Gastric type I carcinoid: a pilot study with human G17DT immunogen vaccination 显示文摘 | Tieppo C Betterle C Basso D | 2011 | Cancer Immunol Immunother2011，60，7： | 1 |
| 12 | Syringomyelia and amold-Chiari malformation associated with neck pain and left arm radiculopathy treated with spinal manipu- lation显示文摘 | Tieppo FV | 2014 | BMJ Case Rep2014，9，20： | 1 |
| 13 | Exit strategies in inflammatory bowel disease:Looking beyond antitumor necrosis factors显示文摘The long-term management of patients with inflammatory bowel disease(IBD)is still a matter of debate,and no clear guidelines have been issued.In clinical practice,gastroenterologists often have to deal with patients in prolonged remission after immunomodulatory or immunosuppressive therapies.When planning an exit strategy for drug withdrawal,the risk of disease relapse must be balanced against the risk of drug-related adverse events and healthcare costs.Furthermore,there is still a dearth of data on the withdrawal of novel biologics,such as the anti-α4β7 integrin antibody(vedolizumab)and anti-IL12/23 antibody(ustekinumab),as well as the small molecule tofacitinib.Models for estimating the risk of disease relapse and the efficacy of retreatment should be evaluated according to the patient's age and IBD phenotype.These models should guide clinicians in programming a temporary drug withdrawal after discussing realistic outcomes with the patient.This would shift the paradigm from an exit strategy to a holiday strategy. | Federica Crispino Andrea Michielan Mauro Grova Chiara Tieppo Marta Mazza Teresa Marzia Rogger Franco Armelao | 2023 | World Journal of Clinical Cases2023，11，12： | 0 |
| 14 | Target-based approach for osteoarthritis treatment显示文摘There is still no definitive treatment for knee osteoarthritis(OA). We are certainly far from a consensus on the best form of treatment or on an effective treatment recommendation. There are reasons for the current equivocal treatment recommendations in the face of this very serious health problem. The greatest of these reasons, undoubtedly, is the great complexity of the factors involved in the development and progression of knee OA and the complex pathophysiology including mechanical, inflammatory, metabolic, post-traumatic, molecular,genetic, and psychological changes. For several years, an attempt has been made to correlate different patient phenotypes to different patterns of response to treatment, thus creating the possibility of developing specific treatments for certain groups of patients and theoretically allowing better treatment efficacy.However, in practice we still find totally different responses and evolutions even in individuals belonging to the same phenotype. Thus, classification by phenotypes, despite being an advance, is not sufficient. The present article proposes a fragmented look at each of the many factors or targets involved in the genesis and evolution of OA. Therefore, we propose not the treatment of OA per se but the management of an individual set of targets to achieve personalized OA management. We believe that, paradoxically, by fragmenting the view of the disease we will be able to treat our patients more holistically in an individualized way. | Gustavo C de Campos Antonio M Tieppo Cyro S de Almeida Jr Paulo C Hamdan Wilson M Alves Márcia U de Rezende | 2020 | World Journal of Orthopedics2020，11，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员